Jaguar Health Inc. has announced the submission of an abstract describing preliminary findings from a clinical trial evaluating a novel oral liquid formulation of crofelemer in adult patients with short bowel syndrome with intestinal failure (SBS-IF). The abstract, submitted by an independent investigator at a leading SBS-IF treatment institution, is under consideration for presentation at the Digestive Disease Week® conference scheduled for May 2-5, 2026. Results from the study have not yet been presented. Crofelemer has received Orphan Drug Designation from both the U.S. Food and Drug Administration and the European Medicines Agency for the treatment of SBS and microvillus inclusion disease (MVID). Jaguar Health and its subsidiary Napo Pharmaceuticals are also conducting additional clinical trials of crofelemer in both adult and pediatric patient populations with intestinal failure.